Effect of continuous positive airway pressure (CPAP) therapy on IL-23 in patients with obstructive sleep apnea

被引:0
作者
Murat Can
Fırat Uygur
Hakan Tanrıverdi
Bilgehan Acıkgoz
Barıs Alper
Berrak Guven
机构
[1] Bulent Ecevit University,Department of Biochemistry, Faculty of Medicine
[2] Bulent Ecevit University,Department of Chest Diseases, Faculty of Medicine
[3] Bulent Ecevit University,Department of Public Health, Faculty of Medicine
[4] Umraniye Education and Training Hospital,Department of Emergency Medicine
来源
Immunologic Research | 2016年 / 64卷
关键词
OSAS; CPAP; IL-23; CRP;
D O I
暂无
中图分类号
学科分类号
摘要
Obstructive sleep apnea syndrome (OSAS) is a common sleep disorder characterized by repeated episodes of apnea and hypopnea during sleep. Continuous positive airway pressure (CPAP) is the most effective method for treating OSAS and alleviating the patients’ symptoms. The aim of this study was to assess the effect of 3-month CPAP therapy on serum levels of IL-23 in patients with OSAS. Twenty-three patients with newly diagnosed moderate-to-severe OSAS who had not yet started nasal CPAP treatment were prospectively enrolled. All of the subjects underwent simple spirometry and an overnight sleep study. Twenty-seven healthy individuals without OSAS were also recruited as the control group. Serum IL-23 and C-reactive protein (CRP) levels were measured before and after 3 months of CPAP therapy. There was no significant difference between moderate and severe OSAS patients in IL-23 and CRP, but both parameters were significantly higher than control group. The CPAP treatment produced a significant decrease in the levels of the inflammatory mediators CRP and IL-23 in patients. Changes in IL-23 were positively correlated with changes in AHI and in CRP. In conclusion, based on these results, serum IL-23 levels reflect OSAS-related systemic inflammation and are a useful marker for improvement in OSAS following CPAP therapy.
引用
收藏
页码:1179 / 1184
页数:5
相关论文
共 116 条
[1]  
Lindberg E(2000)Epidemiology of sleep related obstructive breathing Sleep Med Rev 4 411-433
[2]  
Gislason T(2004)Obstructive sleep apnoea is independently associated with an increased prevalence of metabolic syndrome Eur Heart J 25 735-741
[3]  
Coughlin SR(2005)Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure: an observational study Lancet 365 1046-1053
[4]  
Mawdsley L(2009)Obstructive sleep apnea as a risk factor for type 2 diabetes Am J Med 122 1122-1127
[5]  
Mugarza JA(2006)Serum cardiovascular risk factors in obstructive sleep apnea Chest 129 233-237
[6]  
Calverley PMA(2005)Selective activation of inflammatory pathways by intermittent hypoxia in obstructive sleep apnea syndrome Circulation 112 2660-2667
[7]  
Wilding JPH(2003)Reactive oxygen metabolites (ROMs) as an index of oxidative stress in obstructive sleep apnea patients Sleep Breath 7 105-110
[8]  
Marin JM(2016)Management and risk reduction of rheumatoid arthritis in individuals with obstructive sleep apnea: a nationwide population-based study in Taiwan Sleep 1 515-523
[9]  
Carrizo SJ(2012)Obstructive sleep apnea and the risk of autoimmune diseases: a longitudinal population-based study Sleep Med 13 583-588
[10]  
Vicente E(2011)Interleukin-23: as a drug target for autoimmune inflammatory diseases Immunology 135 112-124